A Study of Parenterally-administered Teverelix TFA in Healthy Male Volunteers

Healthy Clinical Trial

Official title:

A Phase I, Open-label, Single Centre Study Investigating the PK, Safety and PD of a Single Dose of Teverelix TFA, a GnRH Antagonist, Via s.c. or i.m. Route of Administration in Healthy Male Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03781947
• Other study ID #: ANT-1111-P01
• Status: Completed
• Phase: Phase 1
• Start date: November 19, 2018
• Est. completion date: March 16, 2020

Study information

• Verified date: March 2020
• Source: Antev Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Phase I, open-label, single centre study investigating the pharmacokinetics, safety and pharmacodynamics of a single dose of teverelix TFA, a gonadotrophin releasing hormone antagonist, via subcutaneous or intramuscular route of administration in healthy male volunteers

Description:

The primary objective of the study is:

• To characterise the pharmacokinetic (PK) profile of teverelix following single dose, subcutaneous (s.c.) and intramuscular (i.m.) administration of teverelix TFA in healthy male subjects

The secondary objectives of the study are:

• To assess the safety and tolerability of teverelix TFA after single s.c. and i.m. injections in healthy male subjects

• To evaluate pharmacodynamics (PD) effects of teverelix following single dose, s.c. and i.m. administration of teverelix TFA in healthy male subjects

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: March 16, 2020
• Est. primary completion date: March 16, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 40 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Provide voluntarily agreement to participate in this study and sign an Independent Ethics Committee (IEC)-approved informed consent prior to performing any of the screening procedures.

2. Males of any ethnic origin, between 40 to 70 years of age (inclusive) at the screening visit.

3. Healthy, determined by pre-study medical evaluation (medical history, vital signs, physical examination, standard 12-lead ECG and clinical laboratory evaluations).

If a vital sign or ECG assessment is outside of the reference range at the screening visit or admission, the assessment may be repeated once to rule out any error.

4. Body mass index (BMI) between 20.0 and 34.9 kg/m2 (inclusive) at the screening visit and on admission.

Exclusion Criteria:

1. Clinically relevant history of cardiovascular, respiratory, hepatic, renal, pancreatic, gastrointestinal, metabolic, endocrine, neurological, dermatological, immunological, psychiatric or other diseases/disorders as determined by the Principal Investigator or designee, or evidence of such diseases/disorders during the screening period.

2. Any disorder or clinically relevant surgical history that would interfere with the absorption, distribution, metabolism or excretion of the study drug.

3. History of proneness to orthostatic dysregulation, fainting or blackouts.

4. History or physical evidence of chronic or clinically relevant acute infection.

5. Screening total testosterone <3.0 ng/mL (<10.4 nmol/L).

6. History of anaphylactoid reactions or hypersensitivity to teverelix or GnRH antagonists or any of the excipients of the products tested.

7. History of clinically relevant allergies or idiosyncrasies to medication or food.

8. History of regular alcohol consumption exceeding 21 units per week within 2 years of study entry.

9. History of illicit drug abuse within 2 years of study entry.

10. Any ECG abnormality of clinical relevance; ECG QT interval corrected for heart rate using Fridericia's correction (QTcF) > 450 ms at the screening visit.

11. Any clinically relevant findings in the laboratory tests, as judged by the Principal Investigator, at the screening visit and on admission; alanine aminotransferase (ALT) > 1.5 x the upper limit of normal (ULN) and/or aspartate aminotransferase (AST) > 1.5 x ULN and/or total bilirubin > 1.0 x ULN, as confirmed by subsequent repeat assessment, at the screening visit and on admission. If a laboratory assessment is outside of the reference range at the screening visit or admission, the assessment may be repeated once to rule out laboratory error.

12. An estimated glomerular filtration rate (eGFR) < 90 mL/min, based on creatinine clearance calculation by the Cockcroft Gault formula and normalised to an average surface area of 1.73m2, at the screening visit.

13. Positive results in any of the tests for hepatitis B surface antigen (HBsAg), total hepatitis B core antibody (HBcAb), hepatitis C antibody (anti-HCV) or human immunodeficiency virus (HIV) antibodies, at the screening visit.

14. Positive urine test for ethanol and/or drugs of abuse at the screening visit or admission.

15. Use of prescription, non-prescription and over-the-counter (OTC) medications (including vitamins or herbal remedies) within 2 weeks prior to dosing is prohibited.

16. Receiving an investigational product in a clinical trial within 3 months prior to the screening visit.

17. Donation of blood (> 500 mL) or blood products within 2 months (56 days) prior to the screening visit.

18. Unwilling to avoid consumption of coffee and caffeine-containing products within 48 hours prior to admission until discharge from the study centre, as well as from 48 hours before ambulatory visits.

19. Unwilling to avoid use of alcohol or alcohol-containing foods, medications or beverages, within 48 hours prior to admission until discharge from the study centre, as well as from 48 hours before ambulatory visits.

20. Unwilling to abstain from vigorous exercise from 72 hours prior to admission until discharge from the study centre, as well as from 72 hours before ambulatory visits.

21. Unable to understand the protocol requirements, instructions and study related restrictions, the nature, scope and possible consequences of the clinical study.

22. Subject is unlikely to comply with the protocol requirements, instructions and study related restrictions; e.g., uncooperative attitude, inability to return for follow-up visits and improbability of completing the clinical study.

23. Subject has any concurrent condition that, in the opinion of the Principal Investigator, would make the subject unsuitable for participation in the clinical study.

24. Subject is an employee or the close relative of an employee of the Sponsor or the clinical research organisation (CRO) involved in the clinical study.

25. Vulnerable subjects defined as individuals whose willingness to volunteer in a clinical study may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate (e.g., persons in detention, minors and those incapable of giving consent).

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• teverelix TFA
A single s.c. or i.m. injection of teverelix TFA administered on Day 1

Locations

Country	Name	City	State
United Kingdom	PAREXEL International Early Phase Clinical Unit (EPCU)	London	Middlesex

Sponsors (1)

Lead Sponsor	Collaborator
Antev Ltd.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Testosterone (total) levels	Individual data listings of hormone level results will be presented for each subject	12 weeks
Other	Luteinising Hormone (LH) levels	Individual data listings of hormone level results will be presented for each subject	12 weeks
Other	Follicle Stimulating Hormone (FSH) levels	Individual data listings of hormone level results will be presented for each subject	12 weeks
Primary	AUC0-t	Area under the concentration time-curve from time zero up to the last measurable concentration at time point t Area under the concentration time-curve from time zero up to the last measurable concentration at time point t Area under the concentration time-curve from time zero up to the last measurable concentration at time point t	12 weeks
Primary	AUC0-t1	Area under the concentration time-curve from time zero up to concentration at time point t1 after which the concentrations start to rise again towards a second peak, t1 will be determined after review of the concentration-time profiles (immediate release component of total observed AUC)	12 weeks
Primary	AUCt1-t	Area under the concentration time-curve from time point t1 up to time point t (slow release component of total observed AUC)	12 weeks
Primary	AUC0-8	Area under the concentration time-curve from time zero up to infinity (8)	12 weeks
Primary	Cmax	Maximum observed concentration after administration	12 weeks
Primary	Cmax,0-t1	Maximum observed concentration after administration from zero up to time point t1	12 weeks
Primary	Cmax,t1-t	Maximum observed concentration after administration from time point t1 up to time point t	12 weeks
Primary	Tmax	Time to reach Cmax after dosing	12 weeks
Primary	Tmax,0-t1	Time to reach Cmax,0-t1 after dosing	12 weeks
Primary	Tmax,t1-t	Time to reach Cmax,t1-t after dosing	12 weeks
Primary	?z	Apparent terminal rate constant	12 weeks
Primary	t½	Apparent terminal plasma half-life	12 weeks
Secondary	Systemic tolerability - Incidence of Treatment-Emergent Adverse Events	Systemic tolerability assessed by incidence of treatment emergent AEs (TEAEs)	12 weeks
Secondary	Local tolerability - Standardised Injection Site Reaction Scoring System (4-point) plus photography	The injections sites will be assessed (score 0 = none; 1 = mild; 2 = moderate; 3 = severe and undesirable) for signs of erythema, swelling, bruising, itching, pain and other signs of local reactions. Subjects will be monitored for duration of symptoms, sequelae and impact on activities of daily living (ADL). Photographs of all injection sites will be taken at all study visits post-administration	12 weeks
Secondary	Cardiac assessments	The following 12-lead ECG parameters will be assessed: PR interval, QRS interval, RR interval, QT interval and QTc interval (QTcF)	12 weeks
Secondary	24 hour Holter monitoring	Triplicate 10 second 12-lead ECGs will be extracted at time points prior to PK sampling times (Day 1) and matched timepoints (Day -1) in order to facilitate concentration-QTc effect modelling	Day -1 to Day 1